Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Date:10/24/2011

SEATTLE, Oct. 25, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported its financial results for the third quarter ended September 30, 2011.

"This has been a very exciting quarter for the Company as we move pixantrone one step closer to potential approval in both the U.S. and E.U.," noted James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe the data contained in the resubmitted NDA confirms the confidence in the efficacy endpoints and also addresses the other requests made by the Food and Drug Administration (the "FDA"). With the day 180 responses regarding our MAA expected this quarter along with the expected reporting of final data on the tosedostat phase II study at the American Society of Hematology's annual meeting, the fourth quarter is shaping up to reflect the solid progress we have made in 2011."

Recent Highlights

  • Resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") for patients who have failed two or more prior lines of therapy.
  • Announced second independent radiology assessment confirmed the statistical robustness of the PIX301 efficacy data.
  • FDA confirmed that the NDA would receive a six month review after resubmission resulting in potential accelerated approval as early as April 2012.
  • Appointed Reed V. Tuckson, M.D., F.A.C.P., to CTI's Board of Directors. Dr. Tuckson is the Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, the Minnesota-based Fortune 25 diversified health care company that employs more than 87,000 people worldwide and serves more than 75 million Americans. Dr. Tuckson oversees the clinically-related programs of the company's six operating businesses and the work of more than 10,000 clinically-related personnel.  
  • Submitted Day 120 response to the European Medicine Agency's (the "EMA") Committee for Medic
    '/>"/>

  • SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
    (Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
    (Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
    (Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
    Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
    ... China Botanic Pharmaceutical Inc. (NYSE AMEX: ... developer, manufacturer and distributor of botanical products, bio-pharmaceuticals ... announced that the Company successfully showcased its all-natural ... recently held in Chengdu, China. ...
    ... PISGAH FOREST, N.C., May 17, 2011 Responding ... acetaminophen in prescription painkiller combination products, Pisgah Laboratories, ... on abuse deterrent features for opioid drug products. ... ( http://www.uspto.gov ), this new patent application is ...
    ... Masimo (NASDAQ: ... study published in the American Journal of Surgery ... correlates strongly with invasive laboratory hemoglobin testing and "can ... setting and may potentially decrease the invasiveness of both ...
    Cached Biology Technology:China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 2Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 2New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 4New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 6
    (Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
    (Date:4/17/2014)... German . If ... of him, he can expect his premises to be trashed. ... the consequences is enough to make restaurant owners pay up. ... their eggs in other birds, nests. If the host birds ... revenge by destroying the entire nest. Consequently, it is beneficial ...
    (Date:4/17/2014)... Researchers in France have hit on a novel ... receive the correct and most effective treatment possible., ... the western and developing world. If left untreated, ... to renal failure and other complications. In many ... problem. Clearly a more effective pathological approach to ...
    Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
    ... National Laboratory honored more than 165 staff for their ... annual Intellectual Property Commercialization Recognition & Rewards Program banquet. ... materials scientist Jun Liu Inventor of the Year for ... amounts of energy, ease impacts to the electrical grid, ...
    ... at Emory University, along with partners at the Georgia ... over four years to establish the HERCULES Center at ... Exposures). The grant is the first exposome-based center grant ... Center is funded by the National Institute of Environmental ...
    ... wrapping of genomic DNA around nucleosomes in the cell ... of Ludwig-Maximilians-Universitaet (LMU) in Munich now describes a mechanism ... nucleosomes for transcription. In higher organisms the genomic ... disk-shaped particles called nucleosomes, each consisting of two pairs ...
    Cached Biology News:PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2
    ...
    ... All MagCellect Ferrofluid products ... conjunction with R&D Systems MagCellect ... capacities, this neodymium iron boron ... 12 x 75 mm test ...
    S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
    Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
    Biology Products: